Cardiovascular effects of medorinone in ?-adrenoreceptor-blocked and non-blocked anesthetized dogs
- 1 January 1990
- journal article
- research article
- Published by Wiley in Drug Development Research
- Vol. 21 (2) , 119-133
- https://doi.org/10.1002/ddr.430210205
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- Activation of the cAMP system by medorinone correlates with positive inotropy or vasorelaxationDrug Development Research, 1990
- Inhibition of cardiovascular low‐Km cAMP phosphodiesterase activity by medorinoneDrug Development Research, 1990
- Differential Sensitivity to Cardiotonic Drugs of Cyclic AMP Phosphodiesterases Isolated from Canine Ventricular and Sinoatrial-Enriched TissuesJournal of Cardiovascular Pharmacology, 1989
- Electrophysiology of phosphodiesterase inhibitorsThe American Journal of Cardiology, 1989
- Pathophysiology of acute and chronic cardiac failureThe American Journal of Cardiology, 1987
- Cardiohemodynamic Effects of Nipradilol (K-351) in the Dog: Comparison with Propranolol, Nadolol and PrazosinThe Japanese Journal of Pharmacology, 1986
- Comparative effects of propranolol and nadolol on renal blood flow in normal rats and rats with congestive heart failureAmerican Heart Journal, 1984
- Evaluation of a New Bipyridine Inotropic Agent — Milrinone — in Patients with Severe Congestive Heart FailureNew England Journal of Medicine, 1983
- Indices of ventricular contractile state: Comparative sensitivity and specificityAmerican Heart Journal, 1983
- Pharmacology of nadolol (SQ 11725), a β-adrenergic antagonist lacking direct myocardial depressionEuropean Journal of Pharmacology, 1975